This site is intended for health professionals only

MS pill laquinimod shows efficacy at Phase 3


Another pill has shown efficacy at reducing relapses and progression of disability in patients with relapsing–remitting multiple sclerosis, a large Phase 3 study shows.


The oral medicine laquinimod, assessed in 1106 patients from 139 centres in 24 countries, reduced the number of relapses per year by an average of 23% and disability progression by 36%, the team reports in the New England Journal of Medicine. 


The trial assigned patients to receive laquinimod or placebo in a 1:1 ratio for 24 months. 


The “modest” reduction in relapse equated to a significant difference in annualised relapse rate of 0.3 in patients given laquinimod compared with 0.39 in those given placebo (p=0.002). 


Confirmed disability progression was detected in 11.1% of patients on laquinimod, compared with 15.7% of those assigned to receive placebo. 


The researchers, led by G Comi from Universita Vita-Salute San Raffaele in Milan, Italy, concluded: “In this phase 3 study, oral laquinimod administered once daily slowed the progression of disability and reduced the rate of relapse in patients with relapsing–remitting multiple sclerosis.”


New England Journal of Medicine

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine